FGFR1 and mesothelioma: Despite this clinical evidence and the fact that up to 1% of mesothelioma patients might harbor potentially actionable FGFR mutations, the only patient with mesothelioma enrolled in RAGNAR, a phase II trial of erdafitinib in solid tumor with targetable FGFR1/4 alterations (mutations and fusions), did not show a tumoral response when they were treated with the pan-FGFR inhibitor erdafitinib [81].